On the evening of May 20, Jinwright (002723.SZ) announced that the wholly-owned subsidiary Yunhai Venture will invest 22.5 million yuan of its own capital in Ganghua Biology and hold 30% of the shares of Ganghua biology; At the same time, Yunhai venture and Cui Yibing, Shen Zhixiong respectively signed the "equity transfer agreement betting agreement", Cui Yibing, Shen Zhixiong as the core management personnel of Hong Kong China biological yunhai venture to make the following performance commitment: From 2022 to 2024, the after-tax net profit of the parent company after deducting non-recurring gains and losses shall be no less than 4.5 million yuan, 8 million yuan and 10 million yuan.
The popular science
Kingwright is mainly engaged in the r&d, production and sales of rechargeable standby lighting fixtures and rechargeable AC/DC fans.
Since its establishment, Ganghua Bio has focused on the production of high-purity nicotine, which is the upstream business of e-cigarettes.
As one of the scarce enterprises in the field of nicotine production in China, Ganghua Biological has the production qualification of nicotine safety production license, hazardous chemicals registration certificate, sewage discharge license and so on.
Interpretation of the
In November 2021, Kim Wright completed for domestic electronic atomization cigarette brand platinum equity investment, and platinum DE signed the "area" strategic cooperation framework agreement, the platinum's electronic atomization of tobacco products, atomization research and development advantages, and the company's overseas sales channels, production scale and cost advantages, the combination of electronic cigarette business. As an upstream e-cigarette enterprise, The company invested in this investment is conducive to combining the resources and industries of both sides, giving full play to the synergistic effect and deepening the company's layout in the e-cigarette industry.
According to the regulation on e-cigarettes, which was released on April 12, e-cigarette products that do not contain nicotine will not be sold on the market from October 1, 2022, and nicotine extracted from tobacco, or synthetic nicotine, will not be used in e-cigarette compounds in the future.
High-purity nicotine is mainly used in e-cigarettes, medical atomization, and alternative smoking cessation products. Before the new regulation, only Sino Bio and Ganghua had a certain amount of e-cigarette supply, but the scale remained stagnant due to the lack of supply of raw tobacco waste. Caitong Securities estimates that the domestic production of tobacco oil accounts for more than 40% of the world, and the extraction of nicotinoids is gradually shrinking with the decrease of tobacco planting area, and the subsequent supply will continue to be tight.
Data show that in 2021, the number of smokers in the world will be more than 1 billion people, and electronic atomized cigarettes will be used by about 60 million people, with a global penetration rate of 6%, 30% in the United States, 10-15% in Europe and 1-1.5% in China. In the next five years, the compound growth rate of the global industry is expected to be 20%-30%, and China's demand will explode. According to the average nicotine requirement of each electronic atomized cigarette is 20mg/ mL and 3ml, for example, the nicotine requirement of each cigarette is 60mg; About 400 inhalations, 200 a year, so the annual demand for nicotine for one person is about 12g, and the global stock demand is 720 tons. Combined with the loss in the production process and other demands for medical and alternative therapies, the actual demand in 2021 is estimated to be 900-1000 tons.According to the global smokers conversion rate of 30% in the medium term, 300 million smokers, the long-term nicotine demand of e-atomized cigarettes alone is more than 3,600 tons; Combined with the nicotine demand of HERBAL HNB, the total demand will reach more than 5000 tons, and the market capacity will reach 15 billion yuan according to the price center of 3 million yuan/ton. If the high-end demand of medical treatment (smoking cessation lozenges, medical atomization, etc.) is added, the market capacity will be even larger.
The official introduction of the national standard of e-cigarettes marks the end of the disorderly development of China's e-cigarette industry. Guoyuan Securities pointed out that the release of the national standard has put forward higher requirements on the production capacity and technical reserves of e-cigarette sets and bomb manufacturers. Enterprises need to transform from their own internal standards to production in accordance with the national standard, and put forward corresponding requirements for middle and downstream brands and distributors. The industry access threshold will be greatly increased. Enterprises with outstanding comprehensive advantages in process technology and production scale are expected to stand out in the competition, and leading enterprises may further enhance market share by virtue of their own technology and product advantages.
Recent performance of relevant enterprises
In the first quarter of this year, Kinwright achieved revenue of 315 million yuan, up 13.05% year on year; Net profit attributable to shareholders of listed companies was RMB 20 million, up 67.34% year on year.

